4/A
Changes in Ownership
SAB Biotherapeutics, Inc. Filed Acc 0001493152-21-029889
Options or other derivatives
- Chief Science Officer acquired 294,200 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
Bausch Christoph Lawrence · Chief Science Officer
Table II: Derivative
3 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2021-10-22 | Grant or award : show line 1 in the form Employee Stock Option (right to buy) | +104,689 | 104,689 | D |
| 2021-10-22 | Grant or award : show line 2 in the form Employee Stock Option (right to buy) | +81,425 | 81,425 | D |
| 2021-10-22 | Grant or award : show line 3 in the form Earnout Rights (Restricted Stock Units) | +108,086 | 108,086 | D |
Loading xslF345X03/ownership.xml…